Citations

Clear

78 citation(s) found for "Smith, Michael".

Therapeutic Efficacy of Mexiletine for Long QT Syndrome Type 2: Evidence From Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes, Transgenic Rabbits, and Patients
Crotti, Lia , Neves, Raquel , Dagradi, Federica , Musu, Giulia , Giannetti, Federica , Bos, J. Martijn , Barbieri, Miriam , Cerea, Paolo , Giovenzana, Fulvio L F , Torchio, Margherita , Odening, Katja E. , Ackerman, Michael J. , Mura, Manuela , Gnecchi, Massimiliano , Conte, Giulio , Auricchio, Angelo , Sala, Luca , Odening, Katja E , Ackerman, Michael J , Schwartz, Peter J. , Crotti, Lia , Bos, Johan M , Neves, Raquel Almeida Lopes , Dagradi, Federica , Barbieri, Miriam , Conte, Giulio , Sala, Luca

Mayo Clinic

Circulation | June 28, 2024 | Volume: 150 | Issue: 7 | Pages: 531-543

10.1161/circulationaha.124.068959 | PMID 38939955 Get It

BACKGROUND: Despite major advances in the clinical management of long QT syndrome, some patients are not fully protected by beta-blocker therapy. Mexiletine is a well-known sodium channel blocker, with proven efficacy in patients with sodium channel–mediated long QT syndrome type 3. Our aim was to evaluate the efficacy of mexiletine in long QT syndrome type 2 (LQT2) using cardiomyocytes derived from patient-specific human induced pluripotent stem cells, a transgenic LQT2 rabbit model, and patients with LQT2. METHODS: Heart rate–corrected field potential duration, a surrogate for QTc, was measured in human induced pluripotent stem cells from 2 patients with LQT2 (KCNH2-p.A561V, KCNH2-p.R366X) before and after mexiletine using a multiwell multi-electrode array system. Action potential duration at 90% repolarization (APD 90 ) was evaluated in cardiomyocytes isolated from transgenic LQT2 rabbits (KCNH2-p.G628S) at baseline and after mexiletine application. Mexiletine was given to 96 patients with LQT2. Patients were defined as responders in the presence of a QTc shortening ≥40 ms. Antiarrhythmic efficacy of mexiletine was evaluated by a Poisson regression model. RESULTS: After acute treatment with mexiletine, human induced pluripotent stem cells from both patients with LQT2 showed a significant shortening of heart rate–corrected field potential duration compared with dimethyl sulfoxide control. In cardiomyocytes isolated from LQT2 rabbits, acute mexiletine significantly shortened APD 90 by 113 ms, indicating a strong mexiletine-mediated shortening across different LQT2 model systems. Mexiletine was given to 96 patients with LQT2 either chronically (n=60) or after the acute oral drug test (n=36): 65% of the patients taking mexiletine only chronically and 75% of the patients who performed the acute oral test were responders. There was a significant correlation between basal QTc and ∆QTc during the test ( r = −0.8; P <0.001). The oral drug test correctly predicted long-term effect in 93% of the patients. Mexiletine reduced the mean yearly event rate from 0.10 (95% CI, 0.07–0.14) to 0.04 (95% CI, 0.02–0.08), with an incidence rate ratio of 0.40 (95% CI, 0.16–0.84), reflecting a 60% reduction in the event rate ( P =0.01). CONCLUSIONS: Mexiletine significantly shortens cardiac repolarization in LQT2 human induced pluripotent stem cells, in the LQT2 rabbit model, and in the majority of patients with LQT2. Furthermore, mexiletine showed antiarrhythmic efficacy. Mexiletine should therefore be considered a valid therapeutic option to be added to conventional therapies in higher-risk patients with LQT2.
Utilizing median and maximum QTc values improves prediction of breakthrough cardiac events in pediatric long QT syndrome
Rohatgi, Ram K., Tseng, Andrew S. , Sugrue, Alan , Lee, Alexander T. , Wackel, Phillip L., Cannon, Bryan C. , Bos, J. Martijn , Ackerman, Michael J. , Sugrue, Alan , Wackel, Philip , Ackerman, Michael J , Tseng, A S , Bos, Johan M , Scott, Christopher G.

Mayo Clinic

Journal of Cardiovascular Electrophysiology | May 10, 2024 | Volume: 35 | Issue: 7 | Pages: 1370-1381

10.1111/jce.16293 | PMID 38725227 Get It

AbstractIntroductionAlthough prior studies indicate that a QTc > 500 ms on a single baseline 12‐lead electrocardiogram (ECG) is associated with significantly increased risk of arrhythmic events in long QT syndrome (LQTS), less is known about the risk of persistent QT prolongation. We sought to determine QTc persistence and its prognostic effect on breakthrough cardiac events (BCEs) among pediatric patients treated for LQTS.MethodsWe performed a retrospective analysis of 433 patients with LQTS evaluated, risk‐stratified, and undergoing active guideline‐based LQTS treatment between 1999 and 2019. BCEs were defined as arrhythmogenic syncope/seizure, sudden cardiac arrest (SCA), appropriate VF‐terminating ICD shock, and sudden cardiac death (SCD).ResultsDuring the median follow‐up of 5.5 years (interquartile range [IQR] = 3–9), 32 (7%) patients experienced a total of 129 BCEs. A maximum QTc threshold of 520 ms and median QTc threshold of 490 ms were determined to be strong predictors for BCEs. A landmark analysis controlling for age, sex, genotype, and symptomatic status demonstrated models utilizing both the median QTc and maximum QTc demonstrated the highest discriminatory value (c‐statistic = 0.93–0.95). Patients in the high‐risk group (median QTc > 490 ms and maximum QTc > 520 ms) had a significantly lower BCE free survival (70%–81%) when compared to patients in both medium‐risk (93%–97%) and low‐risk (98%–99%) groups.ConclusionsThe risk of BCE among patients treated for LQTS increases not only based upon their maximum QTc, but also their median QTc (persistence of QTc prolongation). Patients with a maximum QTc > 520 ms and median QTc > 490 ms over serial 12‐lead ECGs are at the highest risk of BCE while on guideline‐directed medical therapy.
Genetic testing in early-onset atrial fibrillation
Kany, Shinwan , Jurgens, Sean J. , Rämö, Joel , Rienstra, Michiel , Chung, Mina K. , Ackerman, Michael J. , McNally, Elizabeth M. , Semsarian, Christopher , Wilde, Arthur A.M., Roden, Dan M. , Shoemaker, M. Benjamin , Rienstra, Michiel , Ackerman, Michael J , McNally, Elizabeth M , Semsarian, Christopher , Schnabel, Renate B , Benjamin, Emelia J , Kirchhof, Paulus , Roden, Dan M. , Ellinor, Patrick T , Jurgens, Sean J , Christophersen, Ingrid Elisabeth , Olesen, Morten S. , Schnabel, Renate B. , Benjamin, Emelia J. , Rehm, Heidi L. , Kirchhof, Paulus , Bezzina, Connie R. , Ellinor, Patrick T.

Mayo Clinic

European Heart Journal | May 9, 2024 | Volume: 45 | Issue: 34 | Pages: 3111-3123

10.1093/eurheartj/ehae298 | PMID 39028637 Get It

Abstract Atrial fibrillation (AF) is a globally prevalent cardiac arrhythmia with significant genetic underpinnings, as highlighted by recent large-scale genetic studies. A prominent clinical and genetic overlap exists between AF, heritable ventricular cardiomyopathies, and arrhythmia syndromes, underlining the potential of AF as an early indicator of severe ventricular disease in younger individuals. Indeed, several recent studies have demonstrated meaningful yields of rare pathogenic variants among early-onset AF patients (∼4%–11%), most notably for cardiomyopathy genes in which rare variants are considered clinically actionable. Genetic testing thus presents a promising opportunity to identify monogenetic defects linked to AF and inherited cardiac conditions, such as cardiomyopathy, and may contribute to prognosis and management in early-onset AF patients. A first step towards recognizing this monogenic contribution was taken with the Class IIb recommendation for genetic testing in AF patients aged 45 years or younger by the 2023 American College of Cardiology/American Heart Association guidelines for AF. By identifying pathogenic genetic variants known to underlie inherited cardiomyopathies and arrhythmia syndromes, a personalized care pathway can be developed, encompassing more tailored screening, cascade testing, and potentially genotype-informed prognosis and preventive measures. However, this can only be ensured by frameworks that are developed and supported by all stakeholders. Ambiguity in test results such as variants of uncertain significance remain a major challenge and as many as ∼60% of people with early-onset AF might carry such variants. Patient education (including pretest counselling), training of genetic teams, selection of high-confidence genes, and careful reporting are strategies to mitigate this. Further challenges to implementation include financial barriers, insurability issues, workforce limitations, and the need for standardized definitions in a fast-moving field. Moreover, the prevailing genetic evidence largely rests on European descent populations, underscoring the need for diverse research cohorts and international collaboration. Embracing these challenges and the potential of genetic testing may improve AF care. However, further research—mechanistic, translational, and clinical—is urgently needed.
Motive and opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements (an LLMPP study)
Hilton, Laura K. , Collinge, Brett , Alduaij, Waleed , Shaalan, Haya, Weng, Andrew P. , Cruz, Manuela Martins , Slack, Graham W. , Farinha, Pedro , Miyata‐Takata, Tomoko , Boyle, Merrill, Meissner, Barbara , Cook, James R. , Ondrejka, Sarah L. , Ott, German , Rosenwald, Andreas , Greiner, Timothy C. , Weisenburger, Dennis D. , Chan, Wing C. , Beiske, Klaus, Fu, Kai , Delabie, Jan , Pittaluga, Stafania, Iqbal, Javeed , Wright, George, Staudt, Louis M. , Wright, George W. , Alduaij, Waleed , Weng, Andrew P , Farinha, Pedro , Boyle, Merrill , Cook, James R , Ondrejka, Sarah , Campo, Elías , Amador, Catalina , Greiner, Timothy C , Inghirami, Giorgio , Jaffe, Elaine S , Delabie, Jan , Pittaluga, Stefania , Savage, Kerry J , Mungall, Andrew J , Feldman, Andrew L , Steidl, Christian , Morin, Ryan D , Scott, David W , Iqbal, Javeed , Wright, George , Hilton, Laura K , Ben‐Neriah, Susana , Cruz, Manuela, Campo, Elı́as , Raess, Philipp W. , Song, Joo Y. , Inghirami, Giorgio , Jaffe, Elaine S. , Pittaluga, Stefania , Sehn, Laurie H. , Savage, Kerry J. , Mungall, Andrew J. , Feldman, Andrew L. , Steidl, Christian , Rimsza, Lisa M. , Scott, David W.

Mayo Clinic

Blood | May 3, 2024 | Volume: 144 | Issue: 5 | Pages: 525-540

10.1182/blood.2024024251 | PMID 38701426 Get It

Abstract Rearrangements that place the oncogenes MYC, BCL2, or BCL6 adjacent to superenhancers are common in mature B-cell lymphomas. Lymphomas with diffuse large B-cell lymphoma (DLBCL) or high-grade morphology with both MYC and BCL2 rearrangements are classified as high-grade B-cell lymphoma with MYC and BCL2 rearrangements (“double hit”; HGBCL-DH-BCL2) and are associated with aggressive disease and poor outcomes. Although it is established that MYC rearrangements involving immunoglobulin (IG) loci are associated with inferior outcomes relative to those involving other non-IG superenhancers, the frequency of and mechanisms driving IG vs non-IG MYC rearrangements have not been elucidated. Here, we used custom targeted capture and/or whole-genome sequencing to characterize oncogene rearrangements across 883 mature B-cell lymphomas including Burkitt lymphoma, follicular lymphoma, DLBCL, and HGBCL-DH-BCL2 tumors. We demonstrate that, although BCL2 rearrangement topology is consistent across entities, HGBCL-DH-BCL2 have distinct MYC rearrangement architecture relative to tumors with single MYC rearrangements or with both MYC and BCL6 rearrangements (HGBCL-DH-BCL6), including both a higher frequency of non-IG rearrangements and different architecture of MYC::IGH rearrangements. The distinct MYC rearrangement patterns in HGBCL-DH-BCL2 occur on the background of high levels of somatic hypermutation across MYC partner loci in HGBCL-DH-BCL2, creating more opportunity to form these rearrangements. Furthermore, because 1 IGH allele is already disrupted by the existing BCL2 rearrangement, the MYC rearrangement architecture in HGBCL-DH-BCL2 likely reflects selective pressure to preserve both BCL2 and B-cell receptor expression. These data provide new mechanistic explanations for the distinct patterns of MYC rearrangements observed across different lymphoma entities.
Hypertrophic cardiomyopathy detection with artificial intelligence electrocardiography in international cohorts: an external validation study
Siontis, Konstantinos C. , Wieczorek, Mikolaj A. , Maanja, Maren , Hodge, David O. , Kim, Hyung‐Kwan , Lee, Heesun , Lim, Jaehyun , Ariga, Rina, Mahmod, Masliza , Ackerman, Michael J. , Friedman, Paul A. , Raman, Betty , Mahmod, Masliza , Watkins, Hugh , Neubauer, Stefan , Windecker, Stephan , Ackerman, Michael J , Friedman, Paul A , Kim, Hyung-Kwan , Lee, Hyun‐Jung , Park, Chan Soon , Watkins, Hugh , Windecker, Stephan , Siontis, George C.M. , Gersh, Bernard J. , Attia, Zachi I. , Noseworthy, Peter A.

Mayo Clinic

European Heart Journal - Digital Health | April 13, 2024 | Volume: 5 | Issue: 4 | Pages: 416-426

10.1093/ehjdh/ztae029 | PMID 39081936 Get It

Abstract Aims Recently, deep learning artificial intelligence (AI) models have been trained to detect cardiovascular conditions, including hypertrophic cardiomyopathy (HCM), from the 12-lead electrocardiogram (ECG). In this external validation study, we sought to assess the performance of an AI-ECG algorithm for detecting HCM in diverse international cohorts. Methods and results A convolutional neural network-based AI-ECG algorithm was developed previously in a single-centre North American HCM cohort (Mayo Clinic). This algorithm was applied to the raw 12-lead ECG data of patients with HCM and non-HCM controls from three external cohorts (Bern, Switzerland; Oxford, UK; and Seoul, South Korea). The algorithm’s ability to distinguish HCM vs. non-HCM status from the ECG alone was examined. A total of 773 patients with HCM and 3867 non-HCM controls were included across three sites in the merged external validation cohort. The HCM study sample comprised 54.6% East Asian, 43.2% White, and 2.2% Black patients. Median AI-ECG probabilities of HCM were 85% for patients with HCM and 0.3% for controls (P &lt; 0.001). Overall, the AI-ECG algorithm had an area under the receiver operating characteristic curve (AUC) of 0.922 [95% confidence interval (CI) 0.910–0.934], with diagnostic accuracy 86.9%, sensitivity 82.8%, and specificity 87.7% for HCM detection. In age- and sex-matched analysis (case–control ratio 1:2), the AUC was 0.921 (95% CI 0.909–0.934) with accuracy 88.5%, sensitivity 82.8%, and specificity 90.4%. Conclusion The AI-ECG algorithm determined HCM status from the 12-lead ECG with high accuracy in diverse international cohorts, providing evidence for external validity. The value of this algorithm in improving HCM detection in clinical practice and screening settings requires prospective evaluation.
Insights into adherence to medication and lifestyle recommendations in an international cohort of patients with catecholaminergic polymorphic ventricular tachycardia
Peltenburg, Puck J. , Heuvel, Lieke M. van den , Kallas, Dania , Bell, Cheyanne , Denjoy, Isabelle , Behr, Elijah R. , Kammeraad, Janneke A.E. , Yap, Sing‐Chien , Probst, Vincent , Ackerman, Michael J. , Wilde, Arthur A.M. , van den Heuvel, Lieke M , Kammeraad, Janneke A E , Yap, Sing-Chien , Probst, Vincent , Ackerman, Michael J , Blom, Nico A , Wilde, Arthur A M , Clur, Sally-Ann B , van der Werf, Christian , Behr, Elijah Raphael , Denjoy, Isabelle , Peltenburg, Puck J , Field, Ella , Blom, Nico A. , Clur, Sally‐Ann B. , Werf, Christian van der

Mayo Clinic

Europace | February 13, 2024 | Volume: 26 | Issue: 2 | Pages: No page available

10.1093/europace/euae044 | PMID 38349347 Get It

Abstract Aims In patients with catecholaminergic polymorphic ventricular tachycardia (CPVT), a rare inherited arrhythmia syndrome, arrhythmic events can be prevented by medication and lifestyle recommendations. In patients who experience breakthrough arrhythmic events, non-adherence plays an essential role. We aimed to investigate the incidence and potential reasons for non-adherence to medication and lifestyle recommendations in a large, international cohort of patients with CPVT. Methods and results An online multilingual survey was shared with CPVT patients worldwide by their cardiologists, through peer-recruitment, and on social media from November 2022 until July 2023. Self-reported non-adherence was measured using the validated Medication Adherence Rating Scale (MARS) and a newly developed questionnaire about lifestyle. Additionally, validated questionnaires were used to assess potential reasons for medication non-adherence. Two-hundred-and-eighteen patients completed the survey, of whom 200 (92%) were prescribed medication [122 (61%) female; median age 33.5 years (interquartile range: 22–50)]. One-hundred-and-three (52%) were prescribed beta-blocker and flecainide, 85 (43%) beta-blocker, and 11 (6%) flecainide. Thirty-four (17%) patients experienced a syncope, aborted cardiac arrest or appropriate implantable cardioverter defibrillator shock after diagnosis. Nineteen (13.4%) patients were exercising more than recommended. Thirty (15%) patients were non-adherent to medication. Female sex [odds ratio (OR) 3.7, 95% confidence interval (CI) 1.3–12.0, P = 0.019], flecainide monotherapy compared to combination therapy (OR 6.8, 95% CI 1.6–31.0, P = 0.010), and a higher agreement with statements regarding concerns about CPVT medication (OR 1.2, 95% CI 1.1–1.3, P &lt; 0.001) were independently associated with non-adherence. Conclusion The significant rate of non-adherence associated with concerns regarding CPVT-related medication, emphasizes the potential for improving therapy adherence by targeted patient education.
Risk Prediction in Male Adolescents With Congenital Long QT Syndrome: Implications for Sex‐Specific Risk Stratification in Potassium Channel‐Mediated Long QT Syndrome
Bjelic, Milica , Goldenberg, Ilan , Younis, Arwa , Chen, Anita Y. , Huang, David T. , Yoruk, Ayhan , Aktaş, Mehmet K. , Rosero, Spencer , Cutter, Kristina, McNitt, Scott , Sotoodehnia, Nona , Kudenchuk, Peter J. , Arking, Dan E. , Zaręba, Wojciech , Ackerman, Michael J. , Goldenberg, Ilan , Beinart, Roy , Arking, Dan E , Zareba, Wojciech , Ackerman, Michael J , Goldenberg, Ilan , Huang, David T , Rea, Thomas D.

Mayo Clinic

Journal of the American Heart Association | January 19, 2024 | Volume: 13 | Issue: 3 | Pages: No page available

10.1161/jaha.122.028902 | PMID 38240206 Get It

Background Sex‐specific risk management may improve outcomes in congenital long QT syndrome (LQTS). We recently developed a prediction score for cardiac events (CEs) and life‐threatening events (LTEs) in postadolescent women with LQTS. In the present study, we aimed to develop personalized risk estimates for the burden of CEs and LTEs in male adolescents with potassium channel‐mediated LQTS. Methods and Results The prognostic model was derived from the LQTS Registry headquartered in Rochester, NY, comprising 611 LQT1 or LQT2 male adolescents from age 10 through 20 years, using the following variables: genotype/mutation location, QTc‐specific thresholds, history of syncope, and β‐blocker therapy. Anderson‐Gill modeling was performed for the end point of CE burden (total number of syncope, aborted cardiac arrest, and appropriate defibrillator shocks). The applicability of the CE prediction model was tested for the end point of the first LTE (excluding syncope and adding sudden cardiac death) using Cox modeling. A total of 270 CEs occurred during follow‐up. The genotype–phenotype risk prediction model identified low‐, intermediate‐, and high‐risk groups, comprising 74%, 14%, and 12% of the study population, respectively. Compared with the low‐risk group, high‐risk male subjects experienced a pronounced 5.2‐fold increased risk of recurrent CEs ( P <0.001), whereas intermediate‐risk patients had a 2.1‐fold ( P =0.004) increased risk . At age 20 years, the low‐, intermediate‐, and high‐risk adolescent male patients had on average 0.3, 0.6, and 1.4 CEs per person, respectively. Corresponding 10‐year adjusted probabilities for a first LTE were 2%, 6%, and 8%. Conclusions Personalized genotype–phenotype risk estimates can be used to guide sex‐specific management in male adolescents with potassium channel‐mediated LQTS.
Serum Neurofilament Light Chain Levels (sNfL) Correlate Best with Attack-related Disability in Neuromyelitis Optica (4105)
Atkas, O., Hartung, HP, Smith, Michael , Rees, William A. , Marignier, Romain , Wingerchuk, Dean M. , Green, A., Drappa, Jörn , Barron, Gerard, Madani, S. , She, Dewei, Cimbora, D., Ratchford, John N. , Katz, Eliezer , Fujihara, Kazuo , Paul, Friedemann , Bennett, Jeffrey L. , Kim, H.J., Weinshenker, Brian G. , Pittock, Sean J. , Cutter, Gary , Mealy, Maureen A. , Madani, S., Wang, Lei , Cimbora, Daniel , Cree, Bruce

Mayo Clinic

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.4105 Get It

Pretreatment characteristics associated with symptom reduction during group cognitive processing therapy versus exposure therapy for PTSD: an exploratory study of Veterans
Hunt, Christopher , Casas, Brooks , Chiu, Pearl H. , Smith, Lia J. , Priorello, Laura Jean , Estey, Matthew, Newsome, Mary R. , Williams, Wright , Priorello, Laura , Newsome, Mary R , Williams, M Wright , Lee, Kelly

Mayo Clinic

Cognitive Behaviour Therapy | November 16, 2023 | Volume: 53 | Issue: 1 | Pages: 70-86

10.1080/16506073.2023.2268277 | PMID 37969001 Get It

Association Between Impella Device Support and Elevated Rates of Gout Flares: A Retrospective Analysis
Sinclair, Jorge , Raavi, Lekhya , Narra, Sai Abhishek, Paghdar, Smit , Jonna, Sadhana , SATASHIA, PARTHKUMAR , Hannon, Rachel, Blasavage, Jessica, White, L. O., Olanipekun, Titilope , Kiley, Sean , Leoni, Juan , Nativí, Jose, Lyle, Melissa , Sareyyüpoğlu, Başar , Patel, Parag, Sanghavi, Devang , Isha, Shahin , Olivero, Lorenzo , White, Layton, Bansal, Pankaj , Leoni, Juan Carlos , Thomas, Mathew , Pham, Si M. , Smith, Michael, Franco, Pablo Moreno

Mayo Clinic

No container title available | November 13, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3549951/v1 Get It

Abstract Background Impella is an advanced ventricular assist device frequently used as a bridge to heart transplantation. The association of Impella with increased rates of gout flares has not been studied. Our primary aim is to determine the rates of gout flares in patients on Impella support. Methodology A retrospective study was conducted between January 2017 and September 2022 involving all patients who underwent heart transplantation. The cohort was divided into groups based on Impella support for statistical analysis. In patients receiving Impella support, outcome measures were compared based on the development of gout flares. Results 213 patients were analyzed, with 19.71% supported by Impella. Impella and non-Impella groups had similar age, race, and BMI, but more males were in the Impella group. Gout and chronic kidney disease were more prevalent in Impella-supported patients, while coronary artery disease was less common. The incidence of gout flare was significantly higher in Impella patients (31% vs. 5.3%). The Impella group had an adjusted odds ratio for in-hospital gout flare of 8.069 (95% CI = 2.13–35.08, P = 0.003). Impella-supported patients with gout flares had longer intensive care unit and hospital stays but no difference in mortality or other outcomes. Conclusion Our study is the first to identify the potential association between Impella support and increased rates of gout flares in hospitalized patients. Future studies are required to confirm this association and further elucidate the biological pathways. It is imperative to consider introducing appropriate measures to prevent and promptly manage gout flares in Impella-supported patients.